Subscribe

Lincoln Pharmaceuticals Limited (LINCOLN.NS)

INR603.60 -3.35 (-0.55%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address Lincoln House 380062
Ahmedabad, IN
CEO Mahendrabhai Gulabdas Patel
Website lincolnpharma.com
IPO 2015-12-17
ISIN INE405C01035

Explore sections of this company profile

Also trades on Bombay Stock Exchange · LINCOLN.BO (INR) Bombay Stock Exchange · LINCOPH.BO (INR) National Stock Exchange of India · LINCOLN.NS (INR)
Description

Lincoln Pharmaceuticals Limited, established in 1979 and headquartered in Ahmedabad, India, is a pharmaceutical company engaged in the manufacturing and global distribution of its products. Its comprehensive product line addresses a wide array of medical needs, including dermatological, gynecological, gastrointestinal, and otological conditions. The company also specializes in phosphodiesterase type 5 inhibitors and general anesthetics. Further expanding its therapeutic reach, Lincoln provides treatments for common ailments like coughs, colds, and allergies, alongside anti-asthmatics. Other key product categories include sterile ophthalmic solutions (eye drops and ointments), anti-malarial drugs, and a range of vitamins, minerals, and antioxidants. The portfolio is further diversified with anti-bacterial, anti-viral, and anti-fungal agents; pain relief and fever reduction medications (analgesics and anti-pyretics); and specialized drugs for mental health (anti-psychotics, anti-convulsants, anti-depressants) and diabetes (anti-diabetics). Cardiovascular health is addressed with anti-hypertensives and diuretics, while gastrointestinal issues are targeted with anti-diarrheals, anti-spasmodics, and laxatives. Additionally, the company offers branded generic pharmaceuticals.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR603.60 -3.35 (-0.55%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
155.7K
Beta
0.36
Float Shares
9.00M
Free Float %
44.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-17.17% -14.68% -2.76% -0.49% +22.66% +29.76% +14.70% +64.47% +113.81% +329.96% +187.19%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
603.60
DCF (Unlevered) 1,448.91 +140.0%
DCF (Levered) 2,103.67 +248.5%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Quality scores
Altman Z-Score
7.51
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +7.7% ★ Q1'26: +11.4% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +6.7% Q1'26: +0.5% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +9.5% Q1'26: +20.8% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +12.4% Q1'26: +11.3% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +12.1% ★ Q1'26: +11.3% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.0% Q1'26: 0.0% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.05× ★ Q1'26: 0.04× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.40) × ERP
WACC = 100% × Ke + 0% × Kd (22.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 1,448.73 Current price: 603.60
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
1 Rev. Ana.
1 EPS Ana. 		Mar 2027
1 Rev. Ana.
1 EPS Ana. 		Mar 2028
1 Rev. Ana.
1 EPS Ana. 		Mar 2029
1 Rev. Ana.
1 EPS Ana. 		Mar 2030
1 Rev. Ana.
1 EPS Ana. 		Mar 2031
1 Rev. Ana.
1 EPS Ana. 		Mar 2032
1 Rev. Ana.
1 EPS Ana.
Revenue
2.66B
est: 2.67B (-0.3%)
4.00B
est: 3.44B (+16.2%)
3.50B
est: 3.99B (-12.3%)
3.55B
est: 3.95B (-10.2%)
3.57B
est: 4.01B (-11.1%)
3.77B
est: 4.01B (-5.9%)
4.15B
est: 4.21B (-1.5%)
4.68B
est: 4.68B (+0.1%)
5.05B
est: 6.44B (-21.6%)
5.81B
est: 7.48B (-22.4%)
6.23B
est: 8.82B (-29.3%)
7.48B
7.48B – 7.48B
-15.2% YoY
8.82B
8.82B – 8.82B
+17.9% YoY
4.01B
4.01B – 4.01B
-54.5% YoY
4.01B
4.01B – 4.01B
-0.2% YoY
4.21B
4.21B – 4.21B
+5.2% YoY
4.68B
4.68B – 4.68B
+11.0% YoY
4.68B
4.68B – 4.68B
+0.0% YoY
EBITDA
327.91M
est: 587.57M (-44.2%)
453.74M
est: 757.89M (-40.1%)
485.30M
est: 879.16M (-44.8%)
577.70M
est: 870.15M (-33.6%)
728.92M
est: 883.60M (-17.5%)
760.56M
est: 881.88M (-13.8%)
928.43M
est: 927.31M (+0.1%)
1.05B
est: 1.03B (+2.5%)
1.12B
est: 914.72M (+22.1%)
1.34B
est: 1.65B (-18.4%)
1.24B
est: 1.80B (-31.3%)
1.53B
1.53B – 1.53B
-15.2% YoY
1.80B
1.80B – 1.80B
+17.9% YoY
820.76M
820.76M – 820.76M
-54.5% YoY
819.16M
819.16M – 819.16M
-0.2% YoY
861.36M
861.36M – 861.36M
+5.2% YoY
956.11M
956.11M – 956.11M
+11.0% YoY
956.11M
956.11M – 956.11M
+0.0% YoY
EBIT
276.23M
est: 538.11M (-48.7%)
405.08M
est: 694.09M (-41.6%)
430.15M
est: 805.14M (-46.6%)
507.52M
est: 796.90M (-36.3%)
661.91M
est: 809.22M (-18.2%)
687.30M
est: 807.64M (-14.9%)
849.23M
est: 849.25M (0.0%)
973.91M
est: 942.67M (+3.3%)
1.02B
est: 734.28M (+39.1%)
1.23B
est: 1.51B (-18.3%)
1.11B
est: 1.63B (-32.0%)
1.39B
1.39B – 1.39B
-15.2% YoY
1.63B
1.63B – 1.63B
+17.9% YoY
743.66M
743.66M – 743.66M
-54.5% YoY
742.21M
742.21M – 742.21M
-0.2% YoY
780.45M
780.45M – 780.45M
+5.2% YoY
866.29M
866.29M – 866.29M
+11.0% YoY
866.29M
866.29M – 866.29M
+0.0% YoY
Net Income
150.12M
est: 222.34M (-32.5%)
236.82M
est: 253.79M (-6.7%)
281.23M
est: 284.44M (-1.1%)
346.23M
est: 403.22M (-14.1%)
487.10M
est: 538.23M (-9.5%)
514.39M
est: 547.85M (-6.1%)
622.50M
est: 565.27M (+10.1%)
693.55M
est: 631.78M (+9.8%)
728.99M
est: 648.87M (+12.3%)
933.05M
est: 1.22B (-23.6%)
823.46M
est: 1.44B (-42.9%)
1.22B
1.22B – 1.22B
-15.3% YoY
1.44B
1.44B – 1.44B
+18.0% YoY
538.21M
538.21M – 538.21M
-62.7% YoY
547.82M
547.82M – 547.82M
+1.8% YoY
565.25M
565.25M – 565.25M
+3.2% YoY
631.75M
631.75M – 631.75M
+11.8% YoY
631.75M
631.75M – 631.75M
+0.0% YoY
SGA
316.16M
est: 320.58M (-1.4%)
217.99M
est: 413.51M (-47.3%)
225.86M
est: 479.67M (-52.9%)
267.87M
est: 474.76M (-43.6%)
292.28M
est: 482.10M (-39.4%)
362.12M
est: 481.16M (-24.7%)
349.11M
est: 505.95M (-31.0%)
354.44M
est: 561.60M (-36.9%)
379.50M
est: 739.88M (-48.7%)
1.07B
est: 898.35M (+19.6%)
1.12B
est: 1.27B (-11.5%)
1.08B
1.08B – 1.08B
-15.2% YoY
1.27B
1.27B – 1.27B
+17.9% YoY
578.43M
578.43M – 578.43M
-54.5% YoY
577.30M
577.30M – 577.30M
-0.2% YoY
607.04M
607.04M – 607.04M
+5.2% YoY
673.82M
673.82M – 673.82M
+11.0% YoY
673.82M
673.82M – 673.82M
+0.0% YoY
EPS
9.20
est: 11.10 (-17.1%)
14.52
est: 12.67 (+14.6%)
15.73
est: 14.20 (+10.8%)
17.31
est: 20.13 (-14.0%)
24.36
est: 26.87 (-9.3%)
25.72
est: 27.35 (-6.0%)
31.08
est: 28.22 (+10.1%)
34.63
est: 31.54 (+9.8%)
36.40
est: 51.80 (-29.7%)
46.58
est: 61.00 (-23.6%)
41.11
est: 72.00 (-42.9%)
61.00
61.00 – 61.00
-15.3% YoY
72.00
72.00 – 72.00
+18.0% YoY
26.87
26.87 – 26.87
-62.7% YoY
27.35
27.35 – 27.35
+1.8% YoY
28.22
28.22 – 28.22
+3.2% YoY
31.54
31.54 – 31.54
+11.8% YoY
31.54
31.54 – 31.54
+0.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C 2/5 4/5 1/5 1/5 1/5 3/5 1/5
2026-05-27 C 2/5 4/5 1/5 1/5 1/5 3/5 1/5
2026-05-26 C 2/5 4/5 1/5 1/5 1/5 3/5 1/5
2026-05-25 C 2/5 4/5 1/5 1/5 1/5 3/5 1/5
2026-05-22 C 2/5 4/5 1/5 1/5 1/5 3/5 1/5
2026-05-21 C 2/5 4/5 1/5 1/5 1/5 3/5 1/5
2026-05-20 C 2/5 4/5 1/5 1/5 1/5 3/5 1/5
2026-05-19 C 2/5 4/5 1/5 1/5 1/5 3/5 1/5
2026-05-18 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-05-15 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-05-14 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-05-13 C 2/5 4/5 1/5 1/5 1/5 3/5 1/5
2026-05-12 C 2/5 4/5 1/5 1/5 1/5 3/5 1/5
2026-05-11 C 2/5 4/5 1/5 1/5 1/5 3/5 1/5
2026-05-08 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-05-07 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-05-06 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-05-05 C+ 2/5 4/5 1/5 1/5 1/5 4/5 1/5
2026-05-04 C+ 2/5 5/5 1/5 1/5 1/5 4/5 1/5
2026-04-30 C+ 2/5 5/5 1/5 1/5 1/5 4/5 1/5
2026-04-29 C+ 2/5 5/5 1/5 1/5 1/5 4/5 1/5
2026-04-28 C+ 2/5 5/5 1/5 1/5 1/5 4/5 1/5
2026-04-27 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-24 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-23 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-22 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-21 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-20 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-17 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-16 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
496.05M
OE per share TTM
24.77
Owner's Yield
3.91%
Maintenance CapEx ratio
50.59%
Maint CapEx / Avg PPE
30.2%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
493.1K
Shares Outstanding
20.03M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Munjal Mahendrabhai Patel Whole Time Director 7M male
Hashmukhbhai Ishwarlal Patel Whole Time Director 7M male
Ashish Rajnikant Patel Whole Time Director 7M male
Mahendrabhai Gulabdas Patel MD & Whole Time Director 5M male
Sanjiv Patel Senior Manager of Planning & Administration — male
Amit Dwivedi B-PHARM Group Marketing Manager — male
Trusha Shah Company Secretary & Compliance Officer — female
Darshit Ashvinkumar Shah Chief Financial Officer — male
Laxmikant Harsola Vice President of Technical — male
Sanjay Bhatt Senior Manager of Operation — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic